New oral drug combo shows promise in early cancer trial
NCT ID NCT01534598
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose for future studies, not to prove effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FdCyd (5-fluoro-2'-deoxycytidine) and THU (tetrahydrouridine)
What this could lead to
If this works, it could point toward a new oral treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase I trial with only 59 participants, focused on safety and dosing. It is not yet proven to work, and side effects are unknown. Many early-stage cancer drugs do not advance to become treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Penn State
Hershey, Pennsylvania, 17033, United States
-
UC Davis Cancer Center
Sacramento, California, 95817, United States
-
USC Norris Cancer Center
Los Angeles, California, 90033, United States
-
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232, United States